The antihuman CD25 mAbs basiliximab and daclizumab decrease Treg number and function by blocking IL-2 signaling (45, 46); and daclizumab has been used to deplete Tregs and improve effector responses in human breast cancer vaccine trials (47, 48). Here, IL2 is linked to breast carcinoma.